Clinical Trials and Research Studies
Phase 1
A Phase 1 Open-Label Multicenter Study to Assess the Safety Tolerability and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors
Learn MorePhase 1
A Phase 1 First-in-Human Open Label Dose Escalation Study of MGD009 A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART ) Protein in Patients with Unresectable or Metastatic B7-H3-Expressing Neoplasms and Neoplasms whose Vasculature Expresses
Learn More